Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU
United European Gastroenterology Journal · 2025
DOI: 10.1002/ueg2.12740 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von L Madero-Velázquez und 29 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Hospital General Universitario Dr Balmis de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISAB…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Leishmaniasis, Visceral, Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Leishmaniasis (LI) is a vector‐borne illness caused by a protozoan of the genus Leishmania . Data on the features of LI in patients with inflammatory bowel disease (IBD) are scarce.
Aim
To describe the characteristics of patients with IBD who present with leishmaniasis, infection outcomes and the risk factors associated with developing visceral leishmaniasis (VL).
Methods
An observational retrospective study performed in 26 hospitals in Spain, including all adult patients with IBD who developed Leishmaniasis from 2012 to 2022.
Results
A total of 73 patients were included [mean age 48 years; 65% male; 68% Crohn's disease]. Sixty patients (82.2%) presented localized cutaneous Leishmaniasis (CL), 2 (2.7%) diffuse CL, 3 (4.1%) mucocutaneous Leishmaniasis (MCL) and 8 (11%) VL. All patients were under biologicals (69 [94.5%]) or immunosuppressants (IMM) (4 [5.5%]) at Leishmaniasis diagnosis. AntiTNF was used in 97%, while 2 patients (3%) were receiving ustekinumab. Leishmaniasis resolution was achieved by 48% and 96% of the patients after 1 and 12 months, respectively. Biological withdrawal after Leishmaniasis diagnosis was not statistically related to increased rates of infection resolution among patients with localized CL. Age was the only risk factor associated with VL (OR 1.2, 95%CI 1.04–1.39; p = 0.012).
Conclusions
Leishmaniasis in patients with IBD doesn't seem to follow a complicated clinical course, even in those with localized CL who do not discontinue biological therapy after infection diagnosis. Age might be a risk factor for developing VL. This infection should be considered for immunosuppressed patients with IBD and suggestive symptoms dwelling or travelling to endemic areas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Department, Hospital General Universitario Dr Balmis de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
- Gastroenterology Department, Hospital Policlínico Universitario La Fe, Valencia, Spain.
- Gastroenterology Department, Hospital Universitario Valle de Hebrón, Barcelona, Spain.
- Gastroenterology Department, Hospital Lluis Alcanyis de Xativa, Valencia, Spain.
- Gastroenterology Department, Hospital Universitario Dr Peset, Valencia, Spain.
- Gastroenterology Department, Hospital Arnau de Vilanova, Valencia, Spain.
ORCID-Profile: L Mayorga, L Gimeno-Pitarch, I Ordás, A Martín-Cardona, C Rubín de Célix, L Medina, R Plaza, Y Zabana, A Gutiérrez
Zitieren
APA
Madero-Velázquez, L., Mínguez, A., Mayorga, L., Ramírez, J. J., Moreno, N., Amorós, C., Nieto, M. A., Mena, R., Benítez, J. M., Gimeno-Pitarch, L., Maroto, N., Suria, C., Rodríguez-Moranta, F., Ordás, I., Ruiz, L., García-Brenes, M. A., Martín-Cardona, A., de Célix, C. R., Cárdenas, K., …, & Young Group of GETECCU (2025). Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12740
Vancouver
Madero-Velázquez L, Mínguez A, Mayorga L, Ramírez JJ, Moreno N, Amorós C, et al. Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12740
BibTeX
@article{MaderoVelzquez2025,
author = {Madero-Velázquez, L and Mínguez, A and Mayorga, L and Ramírez, J J and Moreno, N and Amorós, C and Nieto, M A and Mena, R and Benítez, J M and Gimeno-Pitarch, L and Maroto, N and Suria, C and Rodríguez-Moranta, F and Ordás, I and Ruiz, L and García-Brenes, M A and Martín-Cardona, A and de Célix, C Rubín and Cárdenas, K and Ginard, D and Medina, L and Pedrero, N and Plaza, R and Salmoral, R and Martínez-Pérez, T J and Algara, V and Merino, E and Zabana, Y and Gutiérrez, A and Young Group of GETECCU, Young Group of GETECCU},
title = {Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU},
journal = {United European Gastroenterology Journal},
year = {2025},
doi = {10.1002/ueg2.12740}
}
EUVIMED